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Background: Adults born preterm at very low birth weight (VLBW ≤ 1500g) have increased risk factors for
cardiovascular diseases including high blood pressure and impaired glucose regulation. Non-optimal lipoprotein
profile is generally also likely to affect the increased cardiovascular risk, but lipoprotein subclass level data on adults
born at VLBW are sparse.
Subjects and methods: We studied 162 subjects born at VLBW and 169 term-born controls, aged 19 to 27 years.
Total lipid, triglyceride and cholesterol concentrations of 14 lipoprotein subclasses were determined by proton
nuclear magnetic resonance spectroscopy in the fasting state and in 2-hour serum samples from an oral glucose
tolerance test.
Findings: In comparison to controls, VLBW subjects had significantly higher fasting concentration of triglycerides in
chylomicrons and largest very-low-density lipoprotein particles [XXL-VLDL-TG, difference 0.026 (95% CI: 0.004 to
0.049), P = 0.024], and of triglycerides in small high-density lipoprotein particles [S-HDL-TG, 0.026 (95% CI: 0.002 to
0.051), P = 0.037]. The seemingly important role of triglycerides was further supported by principal component
analysis in which the first component was characterized by multiple lipoprotein triglyceride measures.
Conclusions: Young adults born at VLBW and their peers born at term had triglyceride-related differences in both
VLDL and HDL subclasses. These differences suggest that the increased risk factors for cardiovascular diseases
among the VLBW individuals in adulthood may partly relate to impaired triglyceride metabolism.
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Adult-onset cardiovascular diseases have their origins
partly in intrauterine and early postnatal life [1]. As
young adults, very low birth weight (VLBW, ≤1500 g)
infants have increased risk factors for cardiovascular
diseases and type 2 diabetes [2-6]. They have, e.g., higher
blood pressure than their term-born peers, and higher
indexes of insulin resistance and glucose intolerance
[2-6]. Some, although not all, studies have shown asso-
ciations between preterm birth and a higher fat percentage
in adulthood [5,7]. Findings on serum lipid profile are
inconsistent. Although some studies have indicated that* Correspondence: karoliina.wehkalampi@helsinki.fi
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reproduction in any medium, provided the orlow gestational age at birth relates to non-optimal serum
lipids in later life [8-10], most have not reported
dyslipidemia in adults born preterm [2,5,7,11-13]. How-
ever, these studies have been limited to concentrations of
lipids conventionally measured in clinical practice - total,
low-density lipoprotein (LDL) and high-density lipoprotein
(HDL) cholesterol and total triglycerides, whereas lipopro-
tein subclasses may provide a more precise indicator for
atherogenicity [14,15].
Here we investigated lipoprotein metabolism at subclass
level in VLBW and control subjects from the Helsinki
Study of Very Low Birth Weight Adults by proton nuclear
magnetic resonance (NMR) spectroscopy.Subjects and methods
The participants are from a longitudinal follow-up cohort
of subjects born preterm at VLBW between 1978 andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the study participants
Characteristic VLBW
(n = 161)
Term
(n = 163)
P
Women, n (%) 92 (57) 97 (60) 0.8
Men, n (%) 69 (43) 66 (41) 0.8
At birth
Gestational age, mean (SD), wk 29.1 (2.2) 40.1 (1.2) <0.0001
Birth weight, mean (SD), g 1117 (220) 3575 (471) <0.0001
Birth weight SDS, mean (SD), SDS −1.3 (1.5) 0.0 (1.0) <0.0001
SGA, n (%) 54 (34) 0
Parental
Mother’s smoking during pregnancy 30 (19) 25 (15) 0.5
Parental education, n (%) 0.5
Elementary 17 (11) 11 (7)
High school 32 (20) 29 (18)
Intermediate 65 (40) 53 (33)
University 44 (27) 69 (42)
At clinical examination
Age, mean (SD), y 22.4 (2.2) 22.5 (2.2) 0.9
Height, mean (SD), cm
Women 162.1 (7.7) 167.2 (6.8) <0.0001
Men 174.6 (7.8) 180.4 (6.5) <0.0001
Body mass index, mean (SD), kg/m2
Women 22.2 (4.0) 22.8 (3.7) 0.3
Men 22.1 (3.7) 23.2 (3.2) 0.06
Daily smoking, n (%) 35 (22) 54 (33) 0.08
VLBW, very low birth weight (≤1500 g).
SGA, small for gestational age (birth weight < −2SD).
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unit of Children's Hospital, Helsinki University Central
Hospital, Finland. Of the original 335 survivors, 255
VLBW subjects lived in the greater Helsinki area at the
time of follow-up and were invited to a clinical study
together with a sex-, age-, and birth hospital-matched com-
parison group of 314 term-born subjects who were not
small for gestational age (birth weight more than −2 SD)
[16]; 166 VLBW and 172 controls participated. Of these, 4
and 3, respectively, were excluded because of not having
fasted overnight, or being pregnant. Thus, the study finally
included 162 VLBW and 169 term-born control subjects.
None of these were treated with lipid lowering medica-
tion. One subject had type 1 diabetes. All subjects under-
went a 75 g 2-hour oral glucose tolerance test (OGTT),
based on which none had type 2 diabetes [5].
After an overnight fast of at least 8 hours, the clinical
examination included weight and height measurement,
and a 2-hour 75 g OGTT [5]. From both baseline- and
2-hour-sample, blood was drawn for lipoprotein subclass
analysis. Moreover, the participants completed question-
naires that covered their medical history, smoking
habits, and educational level of their parents.
Total lipid (L), triglyceride (TG) and cholesterol (C)
concentrations of 14 lipoprotein subclasses were ana-
lyzed by proton NMR spectroscopy in serum samples.
The details of this methodology have been described
[17,18] and this platform has recently been applied in
large-scale epidemiological and genetic studies [19,20].
The lipoprotein subclass data are as follows: chylomi-
crons and largest (XXL) very-low-density lipoprotein
(VLDL) particles (average particle diameter at least
75 nm); five different VLDL subclasses: very large (XL)
VLDL (average particle diameter of 64.0 nm), large (L)
VLDL (53.6 nm), medium (M) VLDL (44.5 nm), small (S)
VLDL (36.8 nm), and very small (XS) VLDL (31.3 nm);
intermediate-density lipoprotein (IDL) (28.6 nm); three
LDL subclasses: L-LDL (25.5 nm), M-LDL (23.0 nm), and
S-LDL (18.7 nm); and four HDL subclasses: XL-HDL
(14.3 nm), L-HDL (12.1 nm), M-HDL (10.9 nm), and
S-HDL (8.7 nm). Due to resolution and concentration
issues TG and C are not available for every subclass [20].
The mean size for VLDL, LDL, and HDL particles was
calculated by weighting the corresponding subclass dia-
meters with their particle concentrations. IDL particles
were included in the LDL measure. Altogether 44 lipopro-
tein measures were used.
Statistical analyses were conducted using SPSS 17 and
19 software (IBM SPSS, Chicago, IL). Comparison of basic
characteristics between VLBW and term was performed
using t-test for continuous and chi-square -test for
categorical variables. Because of skewed distributions
lipoprotein subclass measurements were transformed as
follows: 0.1 was added to avoid zero-values and naturallogarithm was used to achieve more symmetrical distri-
butions. Distributions were checked after logarithm trans-
formation and those two that were not sufficiently normal
were transformed again. To find a situation where the
residuals of XXL-VLDL-TG and residuals of XXL-VLDL-L
were fairly normal, we utilized the ‘Box-Cox transforma-
tions for linear models’ in the ‘car’-package downloaded in
April 4th, 2013, to R-software, version 2.15.2. Oct 26, 2012.
To avoid non-positive dependent values we added 0.1 to
the dependent prior to the Box-Cox iterative procedure.
The lambdas with maximal log likelihood were -7.3
and -5.3, for the respective outcomes, yielding to our best
transformations for the full models: y’ = (y + 0.1)(lambda-1)/
(lambda), where y = original variable. With these y’ as
dependent in the full models, the resulting in symmetric
distributions of residuals but, unfortunately, with less
pronounced aggregation of mid values.
We used multiple linear regression to compare indivi-
dual lipoprotein subclass measurements between VLBW
and control subjects. We adjusted for confounding factors
in different models. The fully adjusted model included
age, sex, height, highest parental education, body mass
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smoking of the participant (yes/no) as covariates. Addi-
tionally we also adjusted for alcohol use in the fully
adjusted model; dicotomized values for whether the sub-
ject used alcohol weekly to get drunk or not, and whether
the subject ever used alcohol or not. We also adjusted for
fasting and 2-hour glucose concentrations in additionalFigure 1 Middle: All the 44 lipoprotein subclass measures analysed. L
between VLBW and term subjects. Right: Rotated Component Matrix; using
re-organized into 5 components. Bottom: Factor scores from 5 component
at zero indicates no difference, larger values for VLBW subjects are positive
lipoprotein; LDL, low-density lipoprotein; IDL, intermediate-density lipoprot
cholesterol; L, total lipid; PC, principal component).models. We tested group differences in 44 outcome
variables. Many of the lipoprotein measures are highly
correlated and thus we also utilized the principal compo-
nent analysis to reduce the number of outcomes tested
(the FACTOR-program in SPSS, version 19, was used).
We included the five first components as they explained
95% of the variation and only their eigenvalues were1 2 3 4 5
1 L-VLDL-L .983 .131 -.066 .039 -.002
2 L-VLDL-TG .981 .114 -.069 .047 -.011
3 L-VLDL-C .977 .147 -.075 -.021 -.006
4 XL-VLDL-TG .966 .119 -.031 .039 -.083
5 XL-VLDL-L .962 .132 -.022 .033 -.075
6 VLDL-TG .946 .214 -.175 .050 .113
7 M-VLDL-TG .944 .149 -.178 .055 .085
8 M-VLDL-L .938 .217 -.166 .045 .115
9 Serum-TG .904 .342 -.097 .058 .198
10 M-VLDL-C .902 .330 -.135 -.008 .144
11 VLDL-D .900 -.123 -.148 .022 -.194
12 XXL-VLDL-TG .890 .129 .036 .052 -.064
13 XXL-VLDL-L .884 .120 .039 .062 -.048
14 S-VLDL-TG .875 .299 -.273 -.003 .190
15 S-VLDL-L .777 .484 -.280 -.031 .176
16 XS-VLDL-TG .583 .533 -.153 .077 .524
17 S-HDL-TG .493 .410 -.314 .174 .467
18 L-LDL-C .084 .988 -.038 .046 .038
19 LDL-C .151 .983 -.057 .022 -.033
20 L-LDL-L .099 .982 -.007 .079 .106
21 M-LDL-L .201 .971 -.070 .041 -.030
22 M-LDL-C .182 .970 -.104 .002 -.076
23 S-LDL-C .256 .950 -.036 -.002 -.120
24 IDL-C -.020 .933 .088 .097 .266
25 S-LDL-L .304 .930 -.003 .061 -.093
26 IDL-L .032 .903 .093 .141 .361
27 Serum-C .189 .886 .330 .219 .084
28 ApoB .499 .841 -.091 .018 .155
29 XS-VLDL-L .245 .705 -.014 .150 .605
30 S-VLDL-C .589 .658 -.255 -.078 .109
31 IDL-TG .251 .653 .093 .123 .625
32 .414 .594 -.573 -.278 .158
33 XL-HDL-L -.176 -.033 .956 -.122 -.117
34 L-HDL-C -.234 -.150 .936 .166 -.012
35 HDL-D -.263 -.172 .935 .050 .060
36 L-HDL-L -.236 -.111 .919 .258 .082
37 XL-HDL-C -.137 .042 .907 -.198 -.200
38 HDL-C -.180 .077 .879 .420 -.054
39 ApoA1 .074 .285 .831 .455 -.002
40 XL-HDL-TG .261 .179 .800 -.006 .458
41 M-HDL-C .048 .044 .491 .840 .067
42 M-HDL-L .093 .111 .474 .831 .201
43 S-HDL-L .244 .505 -.137 .766 -.006
44 LDL-D -.519 -.070 .005 .057 .744
45 PC1
46 PC2
47 PC3
48 PC4
49 PC5
ApoBtoApoA1
eft: A forrestplot of fully adjusted differences in fasting serum samples
principal component analysis all lipoprotein measures were
s that were entered into multiple linear regression models. Vertical line
differences. (VLBW, very low birth weight, ≤1500 g; HDL, high-density
ein; VLDL, very-low-density lipoprotein; TG, triglycerides; C, total
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versus term) of each individual's Varimax-rotated compo-
nent scores using adjusted linear regression models.
The study was performed according to the declaration
of Helsinki. The study protocol was approved by the
Ethics Committee at the Helsinki and Uusimaa Hospital
District. Written informed consent was obtained from
each participant.Results
VLBW subjects were (Table 1). Using the unadjusted
model, there were no differences in the separate 44
fasting lipoprotein measures between VLBW and term
(data not shown). Fully adjusted regression models for each
measure (Figure 1) showed no group differences in most
values. However, compared with controls, VLBW subjects
had significantly higher concentration of triglycerides in
chylomicrons and largest VLDL particles [XXL-VLDL-TG,
difference 0.026 (95% CI: 0.004 to 0.049), P = 0.024] and
higher total lipids in these particles [XXL-VLDL-L, differ-
ence 0.036 (95% CI 0.005 to 0.037), P = 0.021]. They also
had higher triglycerides in small HDL particles [S-HDL-
TG, difference 0.026 (95% CI: 0.002 to 0.051), P = 0.037].
No differences in these parameters were observed in the
2-hour OGTT samples (data not shown).
XXL-VLDL-TG and XXL-VLDL-L were somewhat
skewed to the right still after the log transformation.
Thus, we transformed them with BoxCox formulas and
analyzed again the effect of VLBW. In result, the
stardardized betas for these two variables changed from
log transformed values to boxcox values: XXL-VLDL-
TG from 0.13 (p = 0.021) to 0.07 (p = 0.236) and XXL-
VLDL-L changed from 0.13 (p = 0.019) to 0.13 (p = 0.20).
Adding alcohol as a covariate in the fully adjusted
model did not change the observed difference in XXL-
VLDL-TG, XXL-VLDL-L, or S-HDL-TG between VLBW
subjects and controls. Neither were these differencesTable 2 B and 95% confidence interval (CI) and P for the diffe
large VLDL (XXL-VLDL-TG), in total lipids in these particles (X
when adjusted for; 1) full model, 2) + alcohol use, 3) + glucose
XXL-VLDL-TG XXL-VLDL-L
B (95% CI) P B (95% CI)
1 0.026 (0.004, 0.049) 0.024 0.036 (0.005,
2a 0.030 (0.007, 0.053) 0.001 0.041 (0.011,
2b 0.028 (0.005, 0.051) 0.016 0.038 (0.008,
3a 0.024 (0.001, 0.047) 0.040 0.033 (0.002,
3b 0.022 (0.001, 0.044) 0.044 0.031 (0.002,
1) full model; adjustment for age, sex, height, highest parental education, body ma
the participant.
2a) full model + adjustment for whether the subject ever drinks alcohol (yes or no).
2b) full model + adjustment for whether the subject uses alcohol to get drunk on w
3a) full model + adjustment for fasting glucose.
3b) full model + adjustment for 2-hour glucose in oral glucose tolerance test.changed after inclusion of fasting or 2-hour glucose as a
covariate in linear regression (Table 2).
We then performed a principal component analysis,
which re-organized all lipoprotein variables into five
uncorrelated components. The rotated component loadings
for the lipoprotein variables (tabled in Figure 1) characterize
principal component 1 (PC1) mainly as a marker of VLDL
and triglycerides and PC2 as a marker of LDL, cholesterol
and apolipoprotein B (ApoB). In a linear regression model,
scores for PC1 were higher in VLBW subjects than in
control subjects [standardized difference 0.12 (95% CI:
0.00 to 0.23), P = 0.049] (Figure 1). Principal component
analysis for 2-hour OGTT samples yielded similarly to five
components. Regarding these components, VLBW and
control subjects scored similarly (P-values ≥ 0.47).
Discussion
We observed that, in comparison to controls, adults
born at VLBW have higher concentrations of triglyce-
rides both in the largest VLDL particles and in small
HDL particles. These potentially atherogenic characte-
ristics of the lipid profile [21] may contribute to an
increased risk of cardiovascular disease in adults born
preterm at VLBW.
In the general population a weak negative correlation
has been reported between birth weight and serum total
cholesterol [22]. Similarly, an inverse correlation has
been reported between gestational age and serum
triglycerides in 11-15-year-olds [8], total cholesterol in
44-45-year-old women [9], and LDL cholesterol and
ApoB among 16-year-old boys [10]. Based on previous
studies on preterm-born subjects, conventionally mea-
sured lipid levels in fasting blood samples are, however,
similar as in term-born individuals [2,5,7,11-13]. For
instance, in the current cohort the levels of total, and
HDL cholesterol, as well as serum triglycerides do not
differ between the VLBW subjects and controls [5].
However, triglycerides in the largest VLDL and smallrence in triglycerides in chylomicrons and extremely
XL-VLDL-L) as well as in small HDL particles (S-HDL-TG)
indices
S-HDL-TG
P B (95% CI) P
0.037) 0.021 0.026 (0.002, 0.051) 0.03
0.072) 0.009 0.030 (0.006, 0.057) 0.016
0.069) 0.014 0.026 (0.002, 0.051) 0.036
0.064) 0.037 0.024 (−0.001, 0.049) 0.059
0.061) 0.040 0.025 (0.001, 0.049) 0.045
ss index, mother’s smoking during pregnancy, and daily smoking of
eekly basis (yes or no).
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born participants. These new extensive lipoprotein data
thus suggest particular impairments in triglyceride me-
tabolism in relation to VLBW. As triglyceride-mediated
pathways are causally related to coronary heart disease
[23] these findings may partly explain the increased risk
for cardiovascular diseases among the VLBW individuals
in adulthood and also lend support for further studies
with more detailed lipoprotein measures [14,15].
A strength of this study is the measurement of exten-
sive lipoprotein subclass data at both in the fasting state
and 2-hours after an oral glucose challenge. We were
also able to adjust for most potential confounding fac-
tors, such as body mass index, smoking, and parental
education. These factors did not explain the observed
difference between VLBW and control subjects. A com-
mon challenge, as also here, in the studies of VLBW
individuals is the relatively small number of study parti-
cipants available. Combined with the rather high num-
ber of lipoprotein measures analysed, this created a
statistically difficult situation; however, the trends for
biologically related variables supported the findings as
well as reduction of the outcome variables using princi-
pal component analysis. The remaining skewedness in
the log-transformed variables may, in general, cause false
negative findings. During the primary analysis, we
further ‘Box-Cox transformed’ the variables when it was
suspected logarithmic transformation did not adequately
remove the skewedness. After this further transform-
ation the difference estimates did not increase, but
decreased, approximately by 50% at maximum. Thus,
these two methods, together with the principal compo-
nent approach, support VLBW adults exhibit a difference
in the extremely large VLBW triglycerides and total lipids.
In conclusion, we found atherogenic characteristics in
the lipoprotein profile of young adults born preterm at
VLBW. The differences between the VLBW and the
term-born individuals were not detectable with conven-
tional lipid measurements. These findings, though sub-
tle, may indicate that impaired triglyceride metabolism
partly contributes to the increased risk for cardiovascu-
lar disease among adults born severely preterm.
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